Novartis signs deal worth up to $3.22B with Alteogen tech
Alteogen (KRX:196170) said it signed a deal with Novartis worth up to $3.22 billion, giving the Swiss drugmaker access to its technology to make injectable versions of intravenous drugs.
South Korea's Alteogen KRX:196170 said on Wednesday it has signed a deal with Novartis BX:NOT worth up to $3.22 billion, giving the Swiss drugmaker access to its technology to make injectable versions of intravenous drugs.Here are the details